WO2005037260A2 - Use of adrenergic alphaze antagonists for the treatment of vasomotor symptoms - Google Patents
Use of adrenergic alphaze antagonists for the treatment of vasomotor symptoms Download PDFInfo
- Publication number
- WO2005037260A2 WO2005037260A2 PCT/US2004/033754 US2004033754W WO2005037260A2 WO 2005037260 A2 WO2005037260 A2 WO 2005037260A2 US 2004033754 W US2004033754 W US 2004033754W WO 2005037260 A2 WO2005037260 A2 WO 2005037260A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- reuptake inhibitor
- pharmaceutically acceptable
- methyl
- ethyl
- receptor antagonist
- Prior art date
Links
- 230000001457 vasomotor Effects 0.000 title claims abstract description 38
- 208000024891 symptom Diseases 0.000 title claims abstract description 36
- 238000011282 treatment Methods 0.000 title claims abstract description 27
- 239000005557 antagonist Substances 0.000 title abstract description 32
- 230000001800 adrenalinergic effect Effects 0.000 title description 9
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims abstract description 113
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims abstract description 112
- 150000001875 compounds Chemical class 0.000 claims abstract description 76
- 238000000034 method Methods 0.000 claims abstract description 58
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims abstract description 52
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims abstract description 32
- 230000009977 dual effect Effects 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims description 78
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims description 75
- 239000002464 receptor antagonist Substances 0.000 claims description 70
- 229940044551 receptor antagonist Drugs 0.000 claims description 70
- UXABARREKCJULM-UHFFFAOYSA-N 2-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-1-ethylimidazole Chemical compound CCN1C=CN=C1CC1OC2=CC=CC=C2OC1 UXABARREKCJULM-UHFFFAOYSA-N 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 41
- 230000000694 effects Effects 0.000 claims description 37
- 229950008608 imiloxan Drugs 0.000 claims description 37
- 206010060800 Hot flush Diseases 0.000 claims description 30
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 21
- 239000004480 active ingredient Substances 0.000 claims description 20
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 18
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims description 17
- 239000003937 drug carrier Substances 0.000 claims description 17
- 229960003914 desipramine Drugs 0.000 claims description 13
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 claims description 12
- -1 2,3-dihydro-1 ,4- benzodioxin-2-yl Chemical group 0.000 claims description 9
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 8
- DXPRUAWQWPNHBR-UHFFFAOYSA-N 2-(2,3-dihydro-1,4-benzodioxin-3-yl)-1-(1-ethylimidazol-2-yl)ethanone Chemical group CCN1C=CN=C1C(=O)CC1OC2=CC=CC=C2OC1 DXPRUAWQWPNHBR-UHFFFAOYSA-N 0.000 claims description 7
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 claims description 4
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims description 4
- SOQWNSFAQIWXJL-UHFFFAOYSA-N 1-[2-(4-benzylpiperazin-1-yl)-1-(4-fluorophenyl)ethyl]cyclohexan-1-ol Chemical compound C1CN(CC=2C=CC=CC=2)CCN1CC(C=1C=CC(F)=CC=1)C1(O)CCCCC1 SOQWNSFAQIWXJL-UHFFFAOYSA-N 0.000 claims description 4
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 4
- 229960002519 amoxapine Drugs 0.000 claims description 4
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 claims description 4
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 claims description 4
- 229960002430 atomoxetine Drugs 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 229960001623 desvenlafaxine Drugs 0.000 claims description 4
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims description 4
- 229960005426 doxepin Drugs 0.000 claims description 4
- 229960002866 duloxetine Drugs 0.000 claims description 4
- 229960004090 maprotiline Drugs 0.000 claims description 4
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 claims description 4
- 229960000600 milnacipran Drugs 0.000 claims description 4
- ITJNARMNRKSWTA-UHFFFAOYSA-N nisoxetine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=CC=C1OC ITJNARMNRKSWTA-UHFFFAOYSA-N 0.000 claims description 4
- 229950004211 nisoxetine Drugs 0.000 claims description 4
- 229960003770 reboxetine Drugs 0.000 claims description 4
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 4
- 229960004688 venlafaxine Drugs 0.000 claims description 4
- GRUIIAQNNWQJPW-UHFFFAOYSA-N 1-[1-(3-chlorophenyl)-2-(4-methylpiperazin-1-yl)ethyl]cyclohexan-1-ol Chemical compound C1CN(C)CCN1CC(C1(O)CCCCC1)C1=CC=CC(Cl)=C1 GRUIIAQNNWQJPW-UHFFFAOYSA-N 0.000 claims description 2
- PZQVDLYPNAADGQ-UHFFFAOYSA-N 1-[1-(3-chlorophenyl)-2-piperazin-1-ylethyl]cyclohexan-1-ol Chemical compound C1CNCCN1CC(C=1C=C(Cl)C=CC=1)C1(O)CCCCC1 PZQVDLYPNAADGQ-UHFFFAOYSA-N 0.000 claims description 2
- YGOUOBPKDDZCPL-UHFFFAOYSA-N 1-[1-(3-fluorophenyl)-2-(4-methylpiperazin-1-yl)ethyl]cyclohexan-1-ol Chemical compound C1CN(C)CCN1CC(C1(O)CCCCC1)C1=CC=CC(F)=C1 YGOUOBPKDDZCPL-UHFFFAOYSA-N 0.000 claims description 2
- LGRZVDOIDOOMRO-UHFFFAOYSA-N 1-[2-(4-methylpiperazin-1-yl)-1-[3-(trifluoromethyl)phenyl]ethyl]cyclohexan-1-ol Chemical compound C1CN(C)CCN1CC(C1(O)CCCCC1)C1=CC=CC(C(F)(F)F)=C1 LGRZVDOIDOOMRO-UHFFFAOYSA-N 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- JFNKXGOEOQCXDM-UHFFFAOYSA-N 2-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-4,4-dimethylisoquinoline-1,3-dione Chemical compound COC1=CC=CC=C1N1CCN(CCN2C(C(C)(C)C3=CC=CC=C3C2=O)=O)CC1 JFNKXGOEOQCXDM-UHFFFAOYSA-N 0.000 claims 10
- YUTGLCAFRPAGFA-UHFFFAOYSA-N 1-[2-(dimethylamino)-1-[3-(trifluoromethyl)phenyl]ethyl]cyclohexan-1-ol Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=CC(C(F)(F)F)=C1 YUTGLCAFRPAGFA-UHFFFAOYSA-N 0.000 claims 3
- ZZLCFHIKESPLTH-UHFFFAOYSA-N 4-Methylbiphenyl Chemical compound C1=CC(C)=CC=C1C1=CC=CC=C1 ZZLCFHIKESPLTH-UHFFFAOYSA-N 0.000 claims 3
- MJCYUVOCINOVJH-UHFFFAOYSA-N 3-methyl-2,3-dihydro-1,4-benzodioxine Chemical compound C1=CC=C2OC(C)COC2=C1 MJCYUVOCINOVJH-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 24
- 102100030140 Thiosulfate:glutathione sulfurtransferase Human genes 0.000 description 24
- 229960002748 norepinephrine Drugs 0.000 description 24
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 24
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 24
- 241000700159 Rattus Species 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 13
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 13
- 229960004127 naloxone Drugs 0.000 description 12
- 239000000262 estrogen Substances 0.000 description 10
- 229940011871 estrogen Drugs 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 238000001690 micro-dialysis Methods 0.000 description 10
- 210000003169 central nervous system Anatomy 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 230000001331 thermoregulatory effect Effects 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 210000003016 hypothalamus Anatomy 0.000 description 8
- 229920000609 methyl cellulose Polymers 0.000 description 8
- 239000001923 methylcellulose Substances 0.000 description 8
- 235000010981 methylcellulose Nutrition 0.000 description 8
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 8
- 210000001428 peripheral nervous system Anatomy 0.000 description 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000000966 norepinephrine reuptake Effects 0.000 description 7
- 229920000136 polysorbate Polymers 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 230000004064 dysfunction Effects 0.000 description 6
- 230000009245 menopause Effects 0.000 description 6
- 229960005181 morphine Drugs 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000002648 combination therapy Methods 0.000 description 5
- 238000007429 general method Methods 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000011552 rat model Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229940090044 injection Drugs 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 206010029410 night sweats Diseases 0.000 description 4
- 230000036565 night sweats Effects 0.000 description 4
- 210000003814 preoptic area Anatomy 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000002876 beta blocker Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229960002896 clonidine Drugs 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 229960003299 ketamine Drugs 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 238000009806 oophorectomy Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000000697 serotonin reuptake Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
- 206010003439 Artificial menopause Diseases 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000033830 Hot Flashes Diseases 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010029216 Nervousness Diseases 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 241000233805 Phoenix Species 0.000 description 2
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 2
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 2
- 208000010340 Sleep Deprivation Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 150000001722 carbon compounds Chemical class 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000009109 curative therapy Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229960002464 fluoxetine Drugs 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
- 229960003132 halothane Drugs 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007915 intraurethral administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001722 neurochemical effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000002997 ophthalmic solution Substances 0.000 description 2
- 229940054534 ophthalmic solution Drugs 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000002638 palliative care Methods 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 206010036601 premature menopause Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000028016 temperature homeostasis Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 2
- 229960000317 yohimbine Drugs 0.000 description 2
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- DJYRRZYQEUBHIZ-UHFFFAOYSA-N 1-[1-(3-chlorophenyl)-2-[4-(3-chlorophenyl)piperazin-1-yl]ethyl]cyclohexan-1-ol Chemical compound C1CN(C=2C=C(Cl)C=CC=2)CCN1CC(C=1C=C(Cl)C=CC=1)C1(O)CCCCC1 DJYRRZYQEUBHIZ-UHFFFAOYSA-N 0.000 description 1
- UBDWZSWMTNSQLG-UHFFFAOYSA-N 1-[1-(3-methoxyphenyl)-2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]cyclopentan-1-ol Chemical compound COC1=CC=CC(C(CN2CCN(CC2)C=2C=C(C=CC=2)C(F)(F)F)C2(O)CCCC2)=C1 UBDWZSWMTNSQLG-UHFFFAOYSA-N 0.000 description 1
- SAJKHRHHDGSJEZ-UHFFFAOYSA-N 2-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-4,4-dimethylisoquinoline-1,3-dione;dihydrochloride Chemical compound Cl.Cl.COC1=CC=CC=C1N1CCN(CCN2C(C(C)(C)C3=CC=CC=C3C2=O)=O)CC1 SAJKHRHHDGSJEZ-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 229920002972 Acrylic fiber Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000639975 Homo sapiens Sodium-dependent noradrenaline transporter Proteins 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 206010033165 Ovarian failure Diseases 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000862969 Stella Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000009956 central mechanism Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 150000004656 dimethylamines Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000009164 estrogen replacement therapy Methods 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 208000002566 gonadal dysgenesis Diseases 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000009097 homeostatic mechanism Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 102000055827 human SLC6A2 Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000022119 inability to concentrate Diseases 0.000 description 1
- 210000004283 incisor Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229940116314 ketaject Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229930013053 morphinan alkaloid Natural products 0.000 description 1
- 208000008013 morphine dependence Diseases 0.000 description 1
- 229940024844 naloxone injection Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- WLGDAKIJYPIYLR-UHFFFAOYSA-N octane-1-sulfonic acid Chemical compound CCCCCCCCS(O)(=O)=O WLGDAKIJYPIYLR-UHFFFAOYSA-N 0.000 description 1
- 239000003401 opiate antagonist Substances 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 231100000539 ovarian failure Toxicity 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000009955 peripheral mechanism Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to the use of compounds and composition of compounds that modulate norepinephrine levels for the treatment of, inter alia, vasomotor symptoms (VMS).
- VMS vasomotor symptoms
- the present invention relates to the use of compounds and compositions of compounds having adrenergiccc2B antagonist activity for the modulation of the norepinephrine system.
- VMS Vasomotor symptoms
- CNS central nervous system
- VMS are the most common symptoms associated with menopause, occurring in 60% to 80% of all women following natural or surgically-induced menopause.
- VMS are likely to be an adaptive response of the central nervous system (CNS) to declining sex steroids.
- CNS central nervous system
- the most effective therapies for VMS are hormone-based treatments, including estrogens and/or some progestins. Hormonal treatments are very effective at alleviating VMS, but they are not appropriate for all women. It is well recognized that VMS are caused by fluctuations of sex steroid levels and can be disruptive and disabling in both males and females.
- a hot flush can last up to thirty minutes and vary in its frequency from several times a week to multiple occurrences per day.
- the patient experiences a hot flush as a sudden feeling of heat that spreads quickly from the face to the chest and back and then over the rest of the body. It is usually accompanied by outbreaks of profuse sweating. It may sometimes occur several times an hour, and it often occurs at night. Hot flushes and outbreaks of sweats occurring during the night can cause sleep deprivation.
- Hot flushes may be even more severe in women treated for breast cancer for several reasons: (1) many survivors of breast cancer are given tamoxifen, the most prevalent side effect of which is hot flush; (2) many women treated for breast cancer undergo premature menopause from chemotherapy; (3) women with a history of breast cancer have generally been denied estrogen therapy because of concerns about potential recurrence of breast cancer (Loblui, et al., Lancet, 2000, 356(9247): 2059-2063).
- VMS The precise mechanism of the VMS is unknown but generally is thought to represent disturbances to normal homeostatic mechanisms controlling thermoregulation and vasomotor activity (Kronenberg et al., "Thermoregulatory Physiology of Menopausal Hot Flashes: A Review,” Can. J. Physiol. Pharmacol., 1987, 65:1312-1324).
- estrogen treatment e.g. estrogen replacement therapy
- relieves the symptoms establishes the link between these symptoms and an estrogen deficiency.
- the menopausal stage of life is associated with a wide range of other acute symptoms, as described above, and these symptoms are generally estrogen responsive.
- estrogens may stimulate the activity of both the norepinephrine (NE) and/or serotonin (5-HT) systems (J. Pharmacology & Experimental Therapeutics, 1986, 236(3) 646-652). It is hypothesized that estrogens modulate NE and 5-HT levels providing homeostasis in the thermoregulatory center of the hypothalamus. The descending pathways from the hypothalamus via brainstem/spinal cord and the adrenals to the skin are involved in maintaining normal skin temperature. The action of NE and 5-HT reuptake inhibitors is known to impinge on both the CNS and peripheral nervous system (PNS).
- PNS peripheral nervous system
- the pathophysiology of VMS is mediated by both central and peripheral mechanisms and, therefore, the interplay between the CNS and PNS may account for the efficacy of dual acting SRI/NRIs in the treatment of thermoregulatory dysfunction.
- the physiological aspects and the CNS/PNS involvement in VMS may account for the lower doses proposed to treat VMS (Loblui, et al., Lancet, 2000, 356:2059-2063; Stearns ef al., JAMA, 2003, 289:2827-2834) compared to doses used to treat the behavioral aspects of depression.
- the interplay of the CNS/PNS in the pathophysiology of VMS and the presented data within this document were used to support the claims that the norepinephrine system could be targeted to treat VMS.
- WO9944601 discloses a method for decreasing hot flushes in a human female by administering fluoxetine.
- thermoregulatory dysfunctions Freedman er a/., Fertility & Sterility, 2000, 74(1): 20- 3). These receptors are located both pre- and post-synaptically and mediate an inhibitory role in the central and peripheral nervous system.
- adrenergic ⁇ 2 receptors There are four distinct subtypes of the adrenergic ⁇ 2 receptors, i.e., are OC2A, 0C2B, «2C anc * ⁇ 2° (Mackinnon et al., TIPS, 1994, 15: 119; French, Pharmacol. Then, 1995, 68: 175).
- thermoregulation Given the complex ultifaceted nature of thermoregulation and the interplay between the CNS and PNS in maintaining thermoregulatory homeostasis, multiple therapies and approaches can be developed to target vasomotor symptoms.
- the present invention focuses on methods directed to these and other important uses.
- the present invention provides methods for treating a subject afflicted with vasomotor symptoms. - -
- the invention is directed to methods for treating a vasomotor symptom in a subject in need thereof, comprising the step of: administering to said subject a composition comprising: an effective amount of an active ingredient consisting essentially of at least one selective adrenergiC ⁇ ⁇ B receptor antagonist or a pharmaceutically acceptable salt thereof.
- the invention is directed to methods for treating a vasomotor symptom in a subject in need thereof, comprising the step of: administering to said subject a composition comprising: an effective amount of at least one selective adrenergic Q 2B receptor antagonist or a pharmaceutically acceptable salt thereof; and an effective amount of at least one norepinephrine reuptake inhibitor (NRI) or a pharmaceutically acceptable salt thereof.
- a composition comprising: an effective amount of at least one selective adrenergic Q 2B receptor antagonist or a pharmaceutically acceptable salt thereof; and an effective amount of at least one norepinephrine reuptake inhibitor (NRI) or a pharmaceutically acceptable salt thereof.
- NRI norepinephrine reuptake inhibitor
- the invention is directed to methods for treating a vasomotor symptom in a subject in need thereof, comprising the step of: administering to said subject a composition comprising: an effective amount of at least one selective adrenergic ⁇ 2B receptor antagonist or a pharmaceutically acceptable salt thereof; and an effective amount of at least one dual norepinephrine reuptake inhibitor/serotonin reuptake inhibitor (NRI/SRI) or a pharmaceutically acceptable salt thereof.
- a composition comprising: an effective amount of at least one selective adrenergic ⁇ 2B receptor antagonist or a pharmaceutically acceptable salt thereof; and an effective amount of at least one dual norepinephrine reuptake inhibitor/serotonin reuptake inhibitor (NRI/SRI) or a pharmaceutically acceptable salt thereof.
- the invention is directed to pharmaceutical compositions, comprising: an active ingredient consisting essentially of at least one selective adrenergiC ⁇ 2B receptor antagonist or a pharmaceutically acceptable salt thereof; and at least one pharmaceutically acceptable carrier.
- an active ingredient consisting essentially of at least one selective adrenergiC ⁇ 2B receptor antagonist or a pharmaceutically acceptable salt thereof; and at least one pharmaceutically acceptable carrier.
- the invention is directed to pharmaceutical compositions, comprising: at least one selective adrenergic ⁇ 2 B receptor antagonist or a pharmaceutically acceptable salt thereof; at least one norepinephrine reuptake inhibitor (NRl) or a pharmaceutically acceptable salt thereof; and at least one pharmaceutically acceptable carrier.
- NRl norepinephrine reuptake inhibitor
- the invention is directed to pharmaceutical compositions, comprising: at least one selective adrenergic 02 B receptor antagonist or a pharmaceutically acceptable salt thereof; at least one norepinephrine reuptake inhibitor/serotonin reuptake inhibitor (NRI/SRI) or a pharmaceutically acceptable salt thereof; and at least one pharmaceutically acceptable carrier.
- at least one selective adrenergic 02 B receptor antagonist or a pharmaceutically acceptable salt thereof at least one norepinephrine reuptake inhibitor/serotonin reuptake inhibitor (NRI/SRI) or a pharmaceutically acceptable salt thereof; and at least one pharmaceutically acceptable carrier.
- NRI/SRI norepinephrine reuptake inhibitor/serotonin reuptake inhibitor
- Figure 2 shows the result of the administration of imiloxan, an adrenergyoc 2 B receptor antagonist, at 2 doses (30 and 60 mg/kg, sc) in telemetry rat model of ovariectomy-induced thermoregulatory dysfunction (referred to in EXAMPLE 2).
- Figure 3 shows the results of the microdialysis studies measuring the effects of imiloxan, an adrenergic 2B receptor antagonist, on extracellular levels of NE and 5-HT in the rat preoptic area of the hypothalamus; imiloxan 10 mg/kg, ip. * indicates p ⁇ 0.05 compared to vehicle control (referred to in EXAMPLE 3).
- Adrenergic ⁇ 2 receptor antagonists are known to induce hot flush.
- a selective adrenergic ⁇ 2 B receptor antagonist when administered alone or when co-administered with a NRl compound, resulted in a dose-dependent abatement of a naloxone-induce flush.
- the efficacy of an NRl may be potentiated when administered in combination with an adrenergic ⁇ 2 ⁇ receptor antagonist. It is believed that the present invention described presents a substantial breakthrough in the field of treatment, alleviation, inhibition, and/or prevention of vasomotor instability and/or symptoms.
- the present invention provides methods for treating a subject afflicted with vasomotor symptoms by of recovering the reduced activity of norepinephrine.
- Norepinephrine activity in the hypothalamus or in the brainstem can be elevated by (i) blocking the activity of the adrenergic ⁇ 2 B receptor with an antagonist and/or (ii) blocking the activity of the NE transporter.
- the present invention provides methods for treating a subject afflicted with vasomotor symptoms comprising administering selective adrenergic ⁇ 2 e antagonists alone, selective adrenergic ⁇ 2B antagonists in combination with norepinephrine reuptake inhibitors (NRl) (as a single compound or as a combination of two or more compounds), or selective adrenergic ⁇ 2 B antagonists in combination with dual norepinephrine reuptake inhibitors/serotonin reuptake inhibitors (NRI/SRI) (as a single compound or as a combination of two or more compounds).
- NRl norepinephrine reuptake inhibitors
- NRI norepinephrine reuptake inhibitors
- the invention also includes pharmaceutical compositions comprising, as the active ingredient(s), selective adrenergic ⁇ 2 B antagonists alone, selective adrenergic ⁇ 2 B antagonists in combination with norepinephrine reuptake inhibitors (NRI) (as a single compound or as a combination of two or more compounds), or selective adrenergic ⁇ 2 ⁇ antagonists in combination with dual norepinephrine reuptake inhibitors/serotonin reuptake inhibitors (NRI/SRI) (as a single compound or as a combination of two or more compounds).
- NRI norepinephrine reuptake inhibitors
- SRI selective adrenergic ⁇ 2 ⁇ antagonists in combination with dual norepinephrine reuptake inhibitors/serotonin reuptake inhibitors
- TST TST skin temperature
- Norepinephrine transporter is abbreviated NET.
- Human norepinephrine transporter is abbreviated hNET.
- SERT Human norepinephrine transporter
- hSERT Human serotonin transporter
- Norepinephrine reuptake inhibitor is abbreviated NRl.
- Selective norepinephrine reuptake inhibitor is abbreviated SNRI.
- SRI Serotonin reuptake inhibitor
- SSRI Selective serotonin reuptake inhibitor
- Norepinephrine is abbreviated NE. - -
- vasomotor symptoms include, but are not limited to, hot flushes (flashes), insomnia, sleep disturbances, mood disorders, irritability, excessive perspiration, night sweats, fatigue, and the like, caused by, inter alia, thermoregulatory dysfunction.
- hot flush is an art-recognized term that refers to an episodic disturbance in body temperature typically consisting of a sudden skin flushing, usually accompanied by perspiration in a subject.
- the term “hot flush” may be used interchangeably with the terms vasomotor symptoms, vasomotor instability, vasomotor dysfunction, night sweats, vasomotor disturbances, and hot flash.
- premenopausal means before the menopause
- perimenopausal means during the menopause
- postmenopausal means after the menopause
- premature menopause or “artificial menopause” refer to ovarian failure of unknown cause that may occur before age 40. It may be associated with smoking, living at high altitude, or poor nutritional status. Artificial menopause may result from oophorectomy, chemotherapy, radiation of the pelvis, or any process that impairs ovarian blood supply.
- ovariectomy means removal of an ovary or ovaries and can be effected according to Merchenthaler et al., Maturitas, 1998; 30(3): 307-316.
- selective adrenergic ⁇ 2 B receptor antagonist refers to an adrenergic ⁇ 2 receptor antagonist compound that preferentially binds to the adrenergic Q 2B receptor relative to the adrenergic ⁇ 2 A receptor or adrenergic ⁇ 2c receptor, and may be measured by the ratio of the in vitro or in vivo IC 50 value for antagonist activity at the adrenergic ⁇ -.B receptor, divided by the IC50 value for antagonist activity at the adrenergic ⁇ 2A or c-
- a selective adrenergic ⁇ 2 B receptor antagonist is any adrenergic ⁇ 2 receptor antagonist for which this ratio is greater than about 1
- norepinephrine reuptake inhibitor refers to a compound that alters the level of norepinephrine (NE) by inhibiting the uptake of NE through neurons of the central and/or peripheral nervous system and/or the peripheral system and that has a selectivity ratio of SERT:NET activity, as measured by the EC 50 value or by % specific bound NE uptake for the human transporter, of at least about 1 :1.
- the selectivity ratio of SERT:NET does not exceed about 1000:1.
- the selectivity ratio of SERT:NET is greater than about 2:1. More preferably, the selectivity ratio of SERT:NET is greater than about 5:1. Even more preferably, the selectivity ratio of SERT:NET is greater than about 10:1.
- substantially no serotonin reuptake inhibitor (SRI) activity refers to a norepinephrine reuptake inhibitor that has a selectivity ratio of SERT:NET activity, as measured by the EC5 0 value or by % specific bound NE uptake for the human transporter, of greater than about 2:1 , preferably, greater than about 5:1 , and more preferably, greater than about 10:1.
- norepinephrine reuptake inhibitor/serotonin reuptake inhibitor refers to a single compound having dual activity as a serotonin reuptake inhibitor and as a norepinephrine reuptake inhibitor.
- a compound having a dual activity is a dual acting compound.
- treatment includes preventative (e.g., prophylactic), curative or palliative treatment and “treating” as used herein also includes preventative, curative and palliative treatment.
- administering means either directly administering a compound or composition of the present invention, or administering a prodrug, derivative or analog which will form an equivalent amount of the active compound or substance within the body.
- effective amount refers to an amount effective, at dosages, and for periods of time necessary, to achieve the desired result.
- effective amount refers to the amount of compound or composition of compounds that would increase norepinephrine levels to compensate in part or total for the lack of steroid availability in subjects subject afflicted with a vasomotor symptom. Varying hormone levels will influence the amount of compound required in the present invention. For example, the pre-menopausal state may require a lower level of compound due to higher hormone levels than the peri-menopausal state.
- the effective amount of components of the present invention will vary from patient to patient not only with the particular compound, component or composition selected, the route of administration, and the ability of the components (alone or in combination with one or more combination drugs) to elicit a desired response in the individual, but also with factors such as the disease state or severity of the condition to be alleviated, hormone levels, age, sex, weight of the individual, the state of being of the patient, and the severity of the pathological condition being treated, concurrent medication or special diets then being followed by the particular patient, and other factors which those skilled in the art will recognize, with the appropriate dosage ultimately being at the discretion of the attendant physician. Dosage regimens may be adjusted to provide the improved therapeutic response.
- a therapeutically effective amount is also one in which any toxic or detrimental effects of the components are outweighed by the therapeutically beneficial effects.
- the compounds of the present invention are administered at a dosage and for a time such that the number of hot flushes is reduced as compared to the number of hot flushes prior to the start of treatment.
- Such treatment can also be beneficial to reduce the overall severity or intensity distribution of any hot flushes still experienced, as compared to the severity of hot flushes prior to the start of the treatment.
- component used interchangeably herein to refer to a compound or compounds or composition of matter which, when administered to an organism (human or animal) induces a desired pharmacologic and/or physiologic effect by local and/or systemic action.
- the component herein may contain norepinephrine reuptake inhibiting activity or combined serotonin reuptake inhibiting activity and the norepinephrine reuptake inhibiting activity.
- the component herein may contain combined norepinephrine reuptake inhibiting activity and the adrenergic ⁇ 2B receptor antagonist activity.
- modulation refers to the capacity to either enhance or inhibit a functional property of a biological activity or process, for example, receptor binding or signaling activity. Such enhancement or inhibition may be contingent on the occurrence of a specific event, such as activation of a signal transduction pathway and/or may be manifest only in particular cell types.
- the modulator is intended to comprise any compound, e.g., antibody, small molecule, peptide, oligopeptide, polypeptide, or protein, preferably small molecule, or peptide.
- the term "combination therapy” refers to the administration of two or more therapeutic agents or compounds to treat a therapeutic condition or disorder described in the present disclosure, for example hot flush, sweating, thermoregulatory-related condition or disorder, or other.
- Such administration includes co-administration of these therapeutic agents or compounds in a simultaneous manner, such as in a single compound having NRI/adrenergic Q 2B receptor antagonist activity or in multiple, separate compounds for each NRl, NRI/SRI or adrenergic ⁇ 2 receptor antagonist activities (including separate compounds administered in a single dosage unit).
- such administration also includes use of each type of therapeutic agent in a concurrent manner. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the conditions or disorders described herein.
- subject refers to an animal including the human species that is treatable with the compositions, and/or methods of the present invention.
- the term “subject” or “subjects” is intended to refer to both the male and female gender unless one gender is specifically indicated. Accordingly, the term “patient” comprises any mammal which may benefit from treatment or prevention of vasomotor disturbances, such as a human, especially if the mammal is female, either in the pre-menopausal, peri-menopausal, or post-menopausal period.
- patient comprises female animals including humans and, among humans, not only women of advanced age who have passed through menopause but also women who have undergone hysterectomy or for some other reason have suppressed estrogen production, such as those who have undergone long-term administration of corticosteroids, suffer from Cushing's syndrome or have gonadal dysgenesis.
- patient is not intended to be limited to a woman.
- side effect refers to a consequence other than the one(s) for which an agent or measure is used, as the adverse effects produced by a drug, especially on a tissue or organ system other then the one sought to be benefited by its administration.
- side effect may refer to such conditions as, for example, vomiting, nausea, sweating, and flushes (Janowsky, et al., Journal of Clinical Psychiatry, 1984, 45(10 Pt 2): 3-9).
- inhibitor is intended to comprise any _ compound, e.g., antibody, small molecule, peptide, oligopeptide, polypeptide, or protein, preferably small molecule or peptide, that exhibits a partial, complete, competitive and/or inhibitory effect on mammalian, preferably the human norepinephrine reuptake or both serotonin reuptake and the norepinephrine reuptake, thus diminishing or blocking, preferably diminishing, some or all of the biological effects of endogenous norepinephrine reuptake or of both serotonin reuptake and the norepinephrine reuptake.
- Suitable non-organic salts include inorganic and organic acids such as acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, malic, maleic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothe ⁇ ic, phosphoric, succinic, sulfuric, tartaric acid, p-toluenesulfonic and the like. Particularly preferred are hydrochloric, hydrobromic, phosphoric, and sulfuric acids, and most preferably is the hydrochloride salt.
- the compounds of the present invention may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like.
- pharmaceutically acceptable solvents such as water, ethanol, and the like.
- the solvated forms are considered equivalent to the unsolvated forms for the purpose of the present invention.
- prodrug means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis) to adrenergic ⁇ 2 B receptor antagonists, NRIs, and NRI/SRIs.
- adrenergic ⁇ 2 B receptor antagonists e.g. by hydrolysis
- NRIs adrenergic ⁇ 2 B receptor antagonists
- NRI/SRIs adrenergic ⁇ 2 B receptor antagonists
- Various forms of prodrugs are known in the art, for example, as discussed in Bundgaard, (ed.), Design of Prodrugs, Elsevier (1985); Widder, et al. (ed.), Methods in Enzymology, vol. 4, Academic Press (1985); Krogsgaard-Larsen, ef al., (ed).
- the invention is directed to methods for treating a vasomotor symptom in a subject in need thereof, comprising the step of: administering to said subject a composition comprising: an effective amount of an active ingredient consisting essentially of at least one selective adrenergic ⁇ 2 B receptor antagonist or a pharmaceutically acceptable salt thereof.
- the invention is directed to methods for treating a vasomotor symptom in a subject in need thereof, comprising the step of: administering to said subject a composition comprising: an effective amount of at least one selective adrenergic ⁇ 2 B receptor antagonist or a pharmaceutically acceptable salt thereof; and an effective amount of at least one norepinephrine reuptake inhibitor (NRl) or a pharmaceutically acceptable salt thereof.
- a composition comprising: an effective amount of at least one selective adrenergic ⁇ 2 B receptor antagonist or a pharmaceutically acceptable salt thereof; and an effective amount of at least one norepinephrine reuptake inhibitor (NRl) or a pharmaceutically acceptable salt thereof.
- the norepinephrine reuptake inhibitor (NRl) is administered simultaneously with the selective adrenergic ⁇ 2B receptor antagonist. In certain other embodiments, the norepinephrine reuptake inhibitor (NRl) is administered sequentially with the selective adrenergic ⁇ 2 B receptor antagonist.
- the selective adrenergic ⁇ 2 B receptor antagonist and the norepinephrine reuptake inhibitor (NRl) are a single compound. In certain embodiments, the selective adrenergic ⁇ 2B receptor antagonist and the norepinephrine reuptake inhibitor (NRl) are separate compounds.
- the norepinephrine reuptake inhibitor has substantially no serotonin reuptake inhibitor (SRI) activity. - -
- the invention is directed to methods for treating a vasomotor symptom in a subject in need thereof, comprising the step of: administering to said subject a composition comprising: an effective amount of at least one selective adrenergic Q 2B receptor antagonist or a pharmaceutically acceptable salt thereof; and an effective amount of at least one dual norepinephrine reuptake inhibitor/serotonin reuptake inhibitor (NRI/SRI) or a pharmaceutically acceptable salt thereof.
- a composition comprising: an effective amount of at least one selective adrenergic Q 2B receptor antagonist or a pharmaceutically acceptable salt thereof; and an effective amount of at least one dual norepinephrine reuptake inhibitor/serotonin reuptake inhibitor (NRI/SRI) or a pharmaceutically acceptable salt thereof.
- the norepinephrine reuptake inhibitor/serotonin reuptake inhibitor is administered simultaneously with the selective adrenergic ⁇ 2 B receptor antagonist. In certain other embodiments, the norepinephrine reuptake inhibitor/serotonin reuptake inhibitor (NRI/SRI) is administered sequentially with the selective adrenergic ⁇ 2 B receptor antagonist.
- the selective adrenergic ⁇ 2B receptor antagonist and the norepinephrine reuptake inhibitor/serotonin reuptake inhibitor are a single compound.
- the selective adrenergic D2B receptor antagonist and the norepinephrine reuptake inhibitor/serotonin reuptake inhibitor are separate compounds.
- the invention is directed to pharmaceutical compositions, comprising: an active ingredient consisting essentially of at least one selective adrenergic ⁇ 2B receptor antagonist or a pharmaceutically acceptable salt thereof; and at least one pharmaceutically acceptable carrier.
- the invention is directed to pharmaceutical compositions, comprising: at least one selective adrenergic ⁇ 2 B receptor antagonist or a pharmaceutically acceptable salt thereof; _ _ at least one norepinephrine reuptake inhibitor (NRl) or a pharmaceutically acceptable salt thereof; and at least one pharmaceutically acceptable carrier.
- the invention is directed to pharmaceutical compositions, comprising: at least one selective adrenergic ⁇ 2 ⁇ receptor antagonist or a pharmaceutically acceptable salt thereof; at least one norepinephrine reuptake inhibitor/serotonin reuptake inhibitor (NRI/SRI) or a pharmaceutically acceptable salt thereof; and at least one pharmaceutically acceptable carrier.
- at least one selective adrenergic ⁇ 2 ⁇ receptor antagonist or a pharmaceutically acceptable salt thereof at least one norepinephrine reuptake inhibitor/serotonin reuptake inhibitor (NRI/SRI) or a pharmaceutically acceptable salt thereof
- NRI/SRI norepinephrine reuptake inhibitor/serotonin reuptake inhibitor
- Suitable selective adrenergic ⁇ 2B receptor antagonist include, but are not limited, to 2-(1-ethyl-2-imidazoyl)methyl-1,4-benzodioxan (imiloxan), 2-[(2,3-dihydro- 1 ,4-benzodioxin-2-yl)methyl]-1 -ethyl-1 H-imidazole, 2-[2-[4-(2-methoxy ⁇ henyl)-1 - piperazinyl]ethyl]-4,4-dimethyl-1 ,3(2H,4H)-isoquinolinedione (ARC 239), or a combination or a pharmaceutically salt thereof.
- Imiloxan is a preferred selective adrenergiC ⁇ B receptor antagonist.
- Suitable norepinephrine reuptake inhibitors include, but are not limited to, maprotiline; reboxetine; norpramine, desipramine; nisoxetine; atomoxetine; amoxapine; doxepin; lofepramin; amitryptyline; 1-[1-(3-fluorophenyl)-2- (4-methyl-1 -piperazinyl)ethyl]cyclohexanol; 1 -[1 -(3-chlorophenyl)-2-(4-methyl-1 - piperazinyl) ethyljcyclohexanol; 1 -[2-(4-methyl-1 -piperazinyl)-1 -[3-(trifluoromethyl)- phenyl]ethyl] cyclohexanol; 1 -[1 -(4-methoxy phenyl)-2-[4-methyl
- Preferred NRIs include is desipramine and 1 -[1 -(3-chlorophenyl)-2-(4- methyl-1-piperazinyl)ethyIjcyc)ohexano), particularly pure R and S enantiomers of 1- [1 -(3-chlorophenyl)-2-(4-methyl-1 -piperazinyl)ethyl]cyclohexanol.
- the dimethyl amine derivatives may be synthesized as described, for example, in US-A- 4,535,186, the disclosure of which is incorporated herein by reference in its entirety.
- the piperazine derivatives may be synthesized as described, for example, in US-A- 4,826,844, the disclosure of which is incorporated herein by reference in its entirety.
- Suitable dual norepinephrine reuptake inhibitor/serotonin reuptake inhibitor (NRI/SRI) compounds are venlafaxine, O-desmethyl-venlafaxine (DVS-233 or ODV), milnacipran, duloxetine, and combinations and pharmaceutically acceptable salts thereof.
- the compound may exhibit more SRI, approximately equivalent NRl and SRI activity, or preferably more NRl activity.
- the adrenergic ⁇ 2 B receptor antagonists, NRIs, and NRI/SRIs may be prepared in the form of pharmaceutically acceptable salts, solvates, and prodrugs.
- Some of the compounds of the present invention may contain chiral centers and such compounds may exist in the form of stereofsomers (i.e. enantiomers).
- the present invention includes all such stereoisomers and any mixtures thereof including racemic mixtures. Racemic mixtures of the stereoisomers as well as the - i - substantially pure stereoisomers are within the scope of the invention.
- the term "substantially pure,” as used herein, refers to at least about 90 mole %, more preferably at least about 95 mole %, and most preferably at least about 98 mole % of the desired stereoisomer is present relative to other possible stereoisomers.
- Preferred enantiomers may be isolated from racemic mixtures by any method known to those skilled in the art, including high performance liquid chromatography (HPLC) and the formation and crystallization of chiral salts or prepared by methods described herein. See, for example, Jacques, et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen, S.H., et al., Tetrahedron, 33:2725 (1977); Eliel, E.L. Stereochemistry of Carbon Compounds, (McGraw-Hill, NY, 1962); Wilen, S.H. Tables of Resolving Agents and Optical Resolutions, p. 268 (E.L. Eliel, Ed., University of Notre Dame Press, Notre Dame, IN 1972).
- HPLC high performance liquid chromatography
- compositions of the present invention contain, as active ingredient(s), selective adrenergic ⁇ 2B antagonists alone, selective adrenergic ⁇ 2B antagonists in combination with norepinephrine reuptake inhibitors (NRl) (as a single compound or as a combination of two or more compounds), or selective adrenergic ⁇ 2 B antagonists in combination with dual norepinephrine reuptake inhibitors/serotonin reuptake inhibitors (NRI/SRI) (as a single compound or as a combination of two or more compounds).
- NRl norepinephrine reuptake inhibitors
- NRI/SRI selective adrenergic ⁇ 2 B antagonists in combination with dual norepinephrine reuptake inhibitors/serotonin reuptake inhibitors
- compositions of the present invention may also comprise at least one pharmaceutically acceptable carrier, adjuvants, and/or excipients, and the like (collectively referred to herein as "pharmaceutically acceptable carrier") that are well known in the art, for example as described in the Hand Book of Pharmaceutical Excipients, second edition, American Pharmaceutical Association, 1994 (incorporated herein by reference).
- pharmaceutically acceptable carrier for example as described in the Hand Book of Pharmaceutical Excipients, second edition, American Pharmaceutical Association, 1994 (incorporated herein by reference).
- the selective adrenergicoc 2B antagonist compound may be administered either alone or in combination therapy with the norepinephrine reuptake inhibitors (NRl) or the norepinephrine reuptake inhibitor/serotonin reuptake inhibitor compounds (NRI/SRI) to patients in the daily dosage range of from about 0.1 to about 500 mg per day for a time sufficient to reduce and/or substantially eliminate the number and/or severity of hot flushes.
- a more preferred range is about 1 to about 300 mg per day, the most preferred daily dosage being about 10 to about 200 mg per day.
- the norepinephrine reuptake inhibitors may be administered in combination therapy with the selective antagonist compound to patients in the daily dosage range of from about 0.1 mg/day to about 500 mg/day for a time sufficient to reduce and/or substantially eliminate the number and/or severity of hot flushes.
- a more preferred range is about 1 mg/day to about 300 mg/day, the most preferred daily dosage being about 1 mg/day to about 200 mg/day.
- the norepinephrine reuptake inhibitor/serotonin reuptake inhibitor compounds (NRI/SRI) in combination therapy with the selective adrenergicoc 2 B antagonist compound may be administered to patients in the daily dosage range of from about 0.10 mg/day to about 200 mg/day for a time sufficient to reduce and/or substantially eliminate the number and/or severity of hot flushes.
- a more preferred range is about 1 mg/day to about 100 mg/day, the most preferred daily dosage being about 10 mg/day to about 50 mg day.
- the selective adrenergic 2B antagonist compound alone or combination therapies of this invention may be in any dosage form, such as those described herein, and can also be administered in various ways, as described herein.
- the combination products of the invention are formulated together, in a single dosage form (that is, combined together in one capsule, tablet, powder, or liquid, etc.).
- the selective adrenergic 2 B antagonists in combination with norepinephrine reuptake inhibitors (NRl), or selective adrenergic ⁇ B antagonists in combination with dual norepinephrine reuptake inhibitors/serotonin reuptake inhibitors (NRI/SRI) may be administered at the same time or simultaneously (that is, together), or in any order.
- the administration of selective adrenergic 2 ⁇ antagonists in combination with norepinephrine reuptake inhibitors (NRl), or selective adrenergica 2 B antagonists in combination with dual norepinephrine reuptake inhibitors/serotonin reuptake inhibitors (NRI/SRI) occurs less than about one hour apart, more preferably less than about 30 minutes apart, even more preferably less than about 15 minutes apart, and still more preferably less than about 5 minutes apart.
- compositions of the invention are prepared in accordance with acceptable pharmaceutical procedures, such as described in Remington's Pharmaceutical Sciences, 17th edition, ed. Alfonoso R. Gennaro, Mack Publishing Company, Easton, PA (1985).
- Pharmaceutically acceptable carriers are those that are compatible with the other ingredients in the formulation and biologically acceptable.
- the compounds and composition of the invention may be administered orally or parenterally, neat or in combination with conventional pharmaceutical carriers.
- Applicable solid carriers can include one or more substances that may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents or an encapsulating material.
- the carrier is a finely divided solid that is in admixture with the finely divided active ingredient.
- the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired.
- the powders and tablets preferably contain up to 99% of the active ingredient.
- Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
- Liquid carriers may be used in preparing solutions, suspensions, emulsions, syrups, and elixirs.
- the active ingredient of this invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat.
- the liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers, or osmo-regulators.
- suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers, or osmo-regulators.
- suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil).
- the carrier can also be an oily ester such as ethyl
- Liquid pharmaceutical compositions which are sterile solutions or suspensions, can be administered by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. Oral administration may be either liquid or solid composition form.
- the pharmaceutical composition is in unit dosage form, e.g. as tablets, capsules, powders, solutions, suspensions, emulsions, granules, or suppositories.
- the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient;
- the unit dosage forms can be packaged compositions, for example packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids.
- the unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.
- the active ingredient(s), (selective adrenergicoc2B antagonist, NRl, or NRI/SRI or a pharmaceutically acceptable salt thereof) will be present at a level of from about 0.1%, by weight, to about 90% by weight, based on the total weight of the pharmaceutical composition, and pharmaceutically acceptable carrier, if present, will be present at a level of from about 0.1%, by weight, to about 90% by weight, based on the total weight of the pharmaceutical composition.
- the active ingredient(s), (selective adrenergic 2 B antagonist, NRl, or NRI/SRI or a pharmaceutically acceptable salt thereof) will be present at a level of from about 1%, by weight, to about 90% by weight, based on the total weight of the pharmaceutical composition, and pharmaceutically acceptable carrier, if present, will be present at a level of from about 1 %, by weight, to about 90% by weight, based on the total weight of the pharmaceutical composition.
- the active ingredient(s), (selective adrenergic ⁇ ,2B antagonist, NRl, or NRI/SRI or a pharmaceutically acceptable salt thereof) will be present at a level of from about 5%, by weight, to about 90% by weight, based on the total weight of the pharmaceutical composition, and pharmaceutically acceptable carrier, if present, will be present at a level of from about 5%, by weight, to about 90% by weight, based on the total weight of the pharmaceutical composition.
- the active ingredient(s), (selective adrenergic ⁇ 2 B antagonist, NRl, or NRI/SRI or a pharmaceutically acceptable salt thereof) will be present at a level of from about 10%, by weight, to about 90% by weight, based on the total weight of the pharmaceutical composition, and pharmaceutically acceptable carrier, if present, will be present at a level of from about 10%, by weight, to about 90% by weight, based on the total weight of the pharmaceutical composition.
- the active ingredient(s), (selective adrenergic ⁇ 2B antagonist, NRl, or NRI/SRI or a pharmaceutically acceptable salt thereof) will be present at a level of from about 25%, by weight, to about 90% by weight, based on the total weight of the pharmaceutical composition, and pharmaceutically acceptable carrier, if present, will be present at a level of from about 25%, by weight, to about 90% by weight, based on the total weight of the pharmaceutical composition.
- the route of administration may be any route, which effectively transports the active ingredient(s) to the appropriate or desired site of action, such as oral, nasal, pulmonary, transdermal, such as passive or iontophoretic delivery, or parenteral, e.g. rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic solution or an ointment.
- Some of the compounds of the present invention may contain chiral centers and such compounds may exist in the form of stereoisomers (i.e. enantiomers).
- the present invention includes all such stereoisomers and any mixtures thereof including racemic mixtures. Racemic mixtures of the stereoisomers as well as the substantially pure stereoisomers are within the scope of the invention.
- the term "substantially pure,” as used herein, refers to at least about 90 mole %, more preferably at least about 95 mole %, and most preferably at least about 98 mole % of the desired stereoisomer is present relative to other possible stereoisomers.
- Preferred enantiomers may be isolated from racemic mixtures by any method known to those skilled in the art, including high performance liquid chromatography (HPLC) and the formation and crystallization of chiral salts or prepared by methods described herein. See, for example, Jacques, et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen, S.H., et al., Tetrahedron, 33:2725 (1977); Eliel, E.L. Stereochemistry of Carbon Compounds, (McGraw-Hill, NY, 1962); Wilen, S.H. Tables of Resolving Agents and Optical Resolutions, p. 268 (E.L. Eliel, Ed., University of Notre Dame Press, Notre Dame, IN 1972).
- HPLC high performance liquid chromatography
- the route of administration may be any route, which effectively transports the active norepinephrine reuptake inhibitor(s) or serotonin reuptake inhibitor(s) and norepinephrine reuptake inhibitor(s) to the appropriate or desired site of action, such as oral, nasal, pulmonary, transdermal, such as passive or iontophoretic delivery, or parenteral, e.g. rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic solution or an ointment. Furthermore, the administration of norepinephrine reuptake inhibitor(s) and serotonin reuptake inhibitor(s) may be concurrent or simultaneous.
- Imiloxan can be purchased commercially (TocrisCookson Inc, Ellisville, MO) Desipramine can be prepared as described in U.S. Pat. No. 3,454,554. The following reagents were purchased commercially: morphine alkaloid pellets (Murty Pharmaceuticals, Lexington, KY),ketamine (Phoenix Pharmaceuticals, Belmont, CA), and naloxone (Research Biochemicals International, St. Louis, MO).
- Dosing All doses were prepared based on mg/kg. Compounds were dissolved in either sterile water, or 2.0% Tween/methylcellulose and injected subcutaneously (sc) or intraperitoneally (ip) and used at the following dosages: imiloxan (1, 10, 15 and 30 mg/kg), desipramine (0.01, 1.0, 10, and 30 mg/kg), Ketamine (Ketaject, Phoenix Pharmaceuticals, Belmont, CA) was injected intramuscularly in the hindlimb at a dosage (40mg/kg) that was determined to be mildly sedative but did not cause a change in tail skin temperature.
- sc subcutaneously
- ip intraperitoneally
- Animals Ovariectomized Sprague-Dawley rats (180-220 g) were obtained from a commercial vendor (Taconic, Germantown, NY) and individually housed under 12 hours light/dark cycle in a room maintained at 25°C.
- male Sprague-Dawley rats (275-350 g) were obtained from Charles River (Wilmington, MA) and group housed until time of surgery. Animals were provided with standard rat chow and water ad libitum.
- Morphine-dependent model Ovariectomized rats were injected once daily for 8-9 days with vehicle to minimize stress responses and then administered compound(s) on test day. On day 4 of dosing, morphine dependence was induced by sc implantation of two slow-release morphine pellets (75 mg/pellet) in the dorsal scapular region. This model is based upon an established morphine-dependent naloxone-induced flush paradigm that is reversible by estrogen treatment (Katovich et al., Proceedings of the Society for Experimental Biology & Medicine, 1990. 193(2): p. 129-35).
- morphine withdrawal was induced with an opioid antagonist (naloxone) that causes a transient increase in TST.
- naloxone an opioid antagonist
- rats were administered their final dose of test compound 40-60 minutes prior to naloxone injection.
- Rats were mildly sedated with ketamine and a thermistor connected to a MacLab data acquisition system was taped to the base of the tail.
- Tail skin temperature was then monitored continuously for 35 minutes to establish a baseline temperature.
- Naloxone was subsequently administered and TST was measured for an additional 35-60 minutes (total recording time 70-95 minutes).
- Telemetry model This model has been modified from a previously reported protocol describing estrogen regulation of diurnal TST patterns (Berendsen et. al., 2001). Over a 24 hour period, intact cycling rats decrease TST during the active (dark) phase and TST remains elevated during the inactive (light) phase. In OVX rats, TST is elevated over the entire 24 hour period, thus the usual decrease in TST during the active (dark) phase is lost, thus, a compound's ability to restore this lowering of TST during the active phase was examined.
- a temperature and physical activity transmitter (PhysioTel TA10TA-F40, Data Sciences International) was implanted subcutaneously in the dorsal scapular region and the tip of the temperature probe was tunneled subcutaneously 2.5 cm beyond the base of the tail. After a 7-day recovery period, TST readings were continuously recorded for the remainder of the study. Tail skin temperature readings were collected from each animal every 5 minutes with values obtained over a 10 second sampling period. The day before test day, an average baseline TST value was calculated for each animal by averaging temperature readings recorded during the 12 hours active (dark) phase. In these studies, animals were dosed approximately 1 hour prior to the onset of dark cycle.
- a microdialysis guide cannula (CMA/12; CMA Microdialysis, Sweden) was directed toward the preoptic area of the hypothalamus using the following coordinates: -0.4 mm anterior to bregma, -1.0 mm lateral from the midline and -6.9 mm ventral to dura with a flat skull (Paxinos and Watson, 1986).
- Guide cannulae were fixed to the skull with two stainless-steel screws (Small Parts, Roanoke, VA) and dental acrylic (Plastics One, Roanoke, VA). Following surgery, animals were individually housed in acrylic cages (45 cm sq.) for approximately 24 hours and had access to food and water ad libitum.
- Microdialysis probes (CMA/12; 20 kD cut-off) were purchased from CMA/Microdialysis and consisted of a 2-mm active membrane (OD 0.5 mm) and 14- mm stainless steel shaft (OD 0.64mm). Probes were perfused with artificial CSF (aCSF; 125 mM NaCI, 3 mM KCI, 0.75 mM MgS0 4 and 1.2 mM CaCI 2 , pH 7.4) according to manufacturer's specifications. On the day of experiments, microdialysis probes were inserted, via the guide cannula, into the hypothalamus and perfused with aCSF at a flow rate of 1 ⁇ l/min.
- CSF artificial CSF
- a 3-hour stabilization period was allowed following probe insertion after which time dialysate was collected every 20 minutes into plastic tubes (CMA) located in a CMA/142 microfraction collector.
- CMA plastic tubes
- Dialysate (10 ⁇ l) containing NE and 5-HT were separated by HPLC (C18 ODS3 column, 150 x 3.0 mm, Metachem, Torrance, CA) and detected using an ANTEC electrochemical detector (ANTEC, Netherlands) set at a potential of 0.65V vs. a Ag/AgCI reference electrode.
- Neurochemical data were compared to an external standard curve and all data was acquired using the Atlas software package (Thermo Labsystems, Beverley, MA) for the PC.
- Efficacy of hot flush abatement was determined by evaluating statistical differences at the peak response time of 15 minutes post-naloxone, when the maximal change in TST is observed.
- a customized SAS-excel (SAS Institute, Cary, NC) application was used applying a four parameter logistic model to determine ED 50 values.
- a logistic dose transformation was performed on ⁇ TST.
- Maximum flush ( ⁇ TST at 15 minutes post-naloxone) was used in the analysis and the minimum was locked at zero.
- the ED 50 value is reported as the dose of test compound that abates 50% of the naloxone- induced flush.
- Statisticians in the Biometrics Department (Wyeth Research, Collegeville, PA) developed a customized JMP application.
- EXAMPLE 1 Effect of a select adrenergic ⁇ 2 B receptor antagonist in alleviating vasomotor instability using a naioxone-induced flush model in rats
- EXAMPLE 2 Effect of a select adrenergic ⁇ 2 ⁇ receptor antagonist in alleviating vasomotor instability using a naioxone-induced flush model in rats [0097] Method used as described in the general method section under telemetry rat model with the following exceptions: Rats were injected subcutaneously with vehicle (2%Tween/0.5% methylcellulose) or 30 or 60 mg/kg, sc imiloxan (Tocris) dissolved in 2%Tween/0.5% methylcellulose. The effect of imiloxan was measured by evaluating the following parameters in this model: onset of action, duration of effect on TST, maximal change in TST and mean change in TST over the duration of the imiloxan's effect. The results are shown in Figure 2.
- Imiloxan (adrenergic 2 ⁇ receptor antagonist) restored normal TST in an OVX-induced thermoregulatory dysfunction telemetry model (telemetry model) 30 mg/kg, sc * indicates p ⁇ 0.05 compared to vehicle control .
- EXAMPLE 3 Effect of compounds with adrenergic ⁇ 2 B receptor antagonist activity and NRl activity
- Rats were injected subcutaneously with vehicle (2%Tween/0.5% methylcellulose) or imiloxan, 15 mg/kg, sc, or desipramine, 1 mg/kg, sc, dissolved in 2%Tween/0.5% methylcellulose 40 minutes prior to a naioxone-induced flush (maximal flush (15 minutes post-naloxone; ⁇ °C, Mean + SEM) the combination of imiloxan and desipramine effectively abated the induced flush.
- naioxone-induced flush maximum flush (15 minutes post-naloxone; ⁇ °C, Mean + SEM
- EXAMPLE 4 Neurochemicaf effect of a select adrenergic ⁇ 2 B receptor antagonist on levels of NE and 5-HT in the preoptic area of the rat hypothalamus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0415280-8A BRPI0415280A (en) | 2003-10-14 | 2004-10-13 | methods for treating vasomotor symptoms |
CA002539757A CA2539757A1 (en) | 2003-10-14 | 2004-10-13 | Use of adrenergic alpha2b antagonists for the treatment of vasomotor symptoms |
JP2006535623A JP2007515395A (en) | 2003-10-14 | 2004-10-13 | How to treat vasomotor symptoms |
EP04794977A EP1846105A2 (en) | 2003-10-14 | 2004-10-13 | Use of adrenergic alpha2b antagonists for the treatment of vasomotor symptoms |
AU2004281750A AU2004281750A1 (en) | 2003-10-14 | 2004-10-13 | Use of adrenergic alphaze antagonists for the treatment of vasomotor symptoms |
MXPA06003866A MXPA06003866A (en) | 2003-10-14 | 2004-10-13 | Method of treating vasomotor symptoms. |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51089703P | 2003-10-14 | 2003-10-14 | |
US10/685,812 US20040152710A1 (en) | 2002-10-15 | 2003-10-14 | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
US60/510,897 | 2003-10-14 | ||
US10/685,812 | 2003-10-14 | ||
PCT/US2003/032759 WO2004035058A1 (en) | 2002-10-15 | 2003-10-15 | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
USPCT/US03/32759 | 2003-10-15 | ||
US10/962,897 | 2004-10-12 | ||
US10/962,897 US20050130987A1 (en) | 2003-10-14 | 2004-10-12 | Methods of treating vasomotor symptoms |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005037260A2 true WO2005037260A2 (en) | 2005-04-28 |
WO2005037260A3 WO2005037260A3 (en) | 2007-08-16 |
Family
ID=34468478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/033754 WO2005037260A2 (en) | 2003-10-14 | 2004-10-13 | Use of adrenergic alphaze antagonists for the treatment of vasomotor symptoms |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1846105A2 (en) |
AU (1) | AU2004281750A1 (en) |
MX (1) | MXPA06003866A (en) |
WO (1) | WO2005037260A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007013936A2 (en) * | 2005-07-21 | 2007-02-01 | Wyeth | Method for treating nervous system disorders and conditions |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2345422A1 (en) * | 1973-09-08 | 1975-03-20 | Thomae Gmbh Dr K | N-Substd.-4,4-dimethyl-isoquinolin-1,3-diones - as hypotensive agents also showing bradycardisant, antiarythmic and sedative effects |
US4302469A (en) * | 1980-09-10 | 1981-11-24 | Syntex (U.S.A.) Inc. | 2-(1,4-Benzodioxan-2-ylalkyl)imidazoles useful as antidepressants |
US4310524A (en) * | 1980-04-11 | 1982-01-12 | Richardson-Merrell, Inc. | TCA Composition and method for rapid onset antidepressant therapy |
EP0303961A2 (en) * | 1987-08-14 | 1989-02-22 | Merrell Dow Pharmaceuticals Inc. | Novel antidepressants |
WO2004035058A1 (en) * | 2002-10-15 | 2004-04-29 | Wyeth | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
WO2004035035A1 (en) * | 2002-10-15 | 2004-04-29 | Wyeth | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
WO2004035036A1 (en) * | 2002-10-15 | 2004-04-29 | Wyeth | A method of treating vasomotor symptoms comprising a compound having norepinephrine reuptake inhibitor activity and 5-ht2a antagonistic activity |
-
2004
- 2004-10-13 EP EP04794977A patent/EP1846105A2/en not_active Withdrawn
- 2004-10-13 WO PCT/US2004/033754 patent/WO2005037260A2/en active Application Filing
- 2004-10-13 AU AU2004281750A patent/AU2004281750A1/en not_active Withdrawn
- 2004-10-13 MX MXPA06003866A patent/MXPA06003866A/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2345422A1 (en) * | 1973-09-08 | 1975-03-20 | Thomae Gmbh Dr K | N-Substd.-4,4-dimethyl-isoquinolin-1,3-diones - as hypotensive agents also showing bradycardisant, antiarythmic and sedative effects |
US4310524A (en) * | 1980-04-11 | 1982-01-12 | Richardson-Merrell, Inc. | TCA Composition and method for rapid onset antidepressant therapy |
US4302469A (en) * | 1980-09-10 | 1981-11-24 | Syntex (U.S.A.) Inc. | 2-(1,4-Benzodioxan-2-ylalkyl)imidazoles useful as antidepressants |
EP0303961A2 (en) * | 1987-08-14 | 1989-02-22 | Merrell Dow Pharmaceuticals Inc. | Novel antidepressants |
WO2004035058A1 (en) * | 2002-10-15 | 2004-04-29 | Wyeth | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
WO2004035035A1 (en) * | 2002-10-15 | 2004-04-29 | Wyeth | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
WO2004035036A1 (en) * | 2002-10-15 | 2004-04-29 | Wyeth | A method of treating vasomotor symptoms comprising a compound having norepinephrine reuptake inhibitor activity and 5-ht2a antagonistic activity |
Non-Patent Citations (4)
Title |
---|
ANON: "IMILOXAN" DRUGS OF THE FUTURE, vol. 11, no. 2, 1986, pages 108-109, XP009044474 ISSN: 0377-8282 * |
BARLOW D H: "Venlafaxine for hot flushes" LANCET, XX, XX, vol. 356, no. 9247, 16 December 2000 (2000-12-16), pages 2025-2026, XP004264301 ISSN: 0140-6736 * |
SHANAFELT TAIT D ET AL: "Pathophysiology and treatment of hot flashes." MAYO CLINIC PROCEEDINGS. NOV 2002, vol. 77, no. 11, November 2002 (2002-11), pages 1207-1218, XP009044403 ISSN: 0025-6196 * |
SLOAN J A ET AL: "Methodologic lessons learned from hot flash studies." JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY. 1 DEC 2001, vol. 19, no. 23, 1 December 2001 (2001-12-01), pages 4280-4290, XP002319050 ISSN: 0732-183X * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007013936A2 (en) * | 2005-07-21 | 2007-02-01 | Wyeth | Method for treating nervous system disorders and conditions |
WO2007013936A3 (en) * | 2005-07-21 | 2007-05-03 | Wyeth Corp | Method for treating nervous system disorders and conditions |
Also Published As
Publication number | Publication date |
---|---|
EP1846105A2 (en) | 2007-10-24 |
AU2004281750A1 (en) | 2005-04-28 |
WO2005037260A3 (en) | 2007-08-16 |
MXPA06003866A (en) | 2006-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080227850A1 (en) | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms | |
US20040063721A1 (en) | Agonism of the 5HT2A receptor for treatment of thermoregulatory dysfunction | |
US20040152710A1 (en) | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms | |
US20040180879A1 (en) | Novel method of treating vasomotor symptoms | |
US20120010260A1 (en) | Method for treating nervous system disorders and conditions | |
US20070021488A1 (en) | Method for treating nervous system disorders and conditions | |
KR20070034129A (en) | Methods of treatment of diseases and disorders of the nervous system | |
US20050130987A1 (en) | Methods of treating vasomotor symptoms | |
WO2005037260A2 (en) | Use of adrenergic alphaze antagonists for the treatment of vasomotor symptoms | |
CA2539757A1 (en) | Use of adrenergic alpha2b antagonists for the treatment of vasomotor symptoms | |
CN101189043A (en) | Use of adrenergic alpha2B antagonists for the treatment of vasomotor symptoms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480037065.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2539757 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004794977 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/003866 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004281750 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006535623 Country of ref document: JP |
|
ENP | Entry into the national phase in: |
Ref document number: 2004281750 Country of ref document: AU Date of ref document: 20041013 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004281750 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1256/KOLNP/2006 Country of ref document: IN |
|
ENP | Entry into the national phase in: |
Ref document number: PI0415280 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004794977 Country of ref document: EP |